Status:
COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HC...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with essential hypertension
- Patients who are eligible and able to participate in the study
- Exclusion Criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
641 Patients enrolled
Trial Details
Trial ID
NCT00219193
Start Date
October 1 2005
End Date
January 1 2007
Last Update
February 7 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany